Literature DB >> 27725337

Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.

Patricia Pérez-Matute1, José G Pichel2, María Iñiguez3, Emma Recio-Fernández1, Laura Pérez-Martínez1, Raquel Torrens2, José Ramón Blanco1, José Antonio Oteo1.   

Abstract

BACKGROUND: Any strategy designed to decrease the macrophage content in adipose tissue (AT) is of great value as a way to decrease inflammation in this fat depot and also as a way to prevent or treat obesity and associated disorders. Maraviroc (MVC), a CCR5 antagonist approved for the treatment of HIV-infected patients, has beneficial effects on metabolism. The objective of this study was to investigate the effects of MVC on AT macrophage recruitment in a mouse model of obesity. The plausible underlying mechanisms of action were also investigated.
METHODS: 32 male C57BL/6 mice were randomly assigned to the following groups: control, MVC (300 mg/l MVC in drinking water), high-fat diet (HFD) or HFD+MVC. After 16 weeks of treatment, histopathological and molecular analyses were performed on epididymal fat.
RESULTS: Our results demonstrated that MVC reduced the presence of macrophages in epididymal fat despite the ingestion of an HFD. The inhibition of MCP-1 gene expression and JNK signalling pathway along with the upregulation of protective cytokines such as cardiotrophin-1 could contribute to these actions. MVC effects on AT macrophage recruitment were associated with a lower body weight gain and a partial improvement in insulin resistance despite an HFD.
CONCLUSIONS: We have demonstrated the ability of MVC to ameliorate the increased AT macrophage recruitment induced by an HFD in a mouse model of obesity. These actions could be of interest when designing antiretroviral treatments in HIV-patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27725337     DOI: 10.3851/IMP3099

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  2 in total

Review 1.  Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Authors:  Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo
Journal:  Int J Mol Sci       Date:  2017-08-15       Impact factor: 5.923

2.  Implications of maraviroc and/or rapamycin in a mouse model of fragility.

Authors:  Laura Pérez-Martínez; Lourdes Romero; Sandra Muñoz-Galván; Eva M Verdugo-Sivianes; Susana Rubio-Mediavilla; José A Oteo; Amancio Carnero; José-Ramón Blanco
Journal:  Aging (Albany NY)       Date:  2020-04-30       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.